Innovative Treatment for Major Depressive Disorder
Brainsway* has introduced a new approach in major depressive disorder treatment, with a safe, effective* medication-free solution which can restore wellbeing. Brainsway's Deep TMS, or Transcranial Magnetic Stimulation, is a non-invasive treatment which can stimulate the brain region responsible for major depressive disorder and create substantial improvement.
Short Sessions, Effective for a Range of Depression Cases
Brainsway's TMS therapy is effecive for a wide range of depression cases - from mild to persistent drug-resistant depression*. An outpatient procedure, Brainsway TMS therapy sessions provide effective results in nearly half the time (just 20 minutes compared to 37 with traditional TMS therapy). Furthermore, the treatment does not require anesthesia, and entails no memory loss and no systemic long term side effects*.
Deep Stimulation Leads to an Enhanced Effect
Studies have shown that the depth and wide range of brain stimulation may have a significant and positive impact on major depressive disorder treatment results, as follows:
- “Many behavioral manifestations of neurological and psychiatric diseases are not solely the result of abnormality in one isolated brain region but represent alterations in brain networks and connectivity.” (Fox et al. Neuroimage 2012)
- "The DLPFC has some of the largest and most reproducible individual differences in functional connectivity across any area of the cortex.“ (Fox et al. Neuroimage 2013)
- “Antidepressant efficacy of different left DLPFC TMS sites is related to the anticorrelation of each site with the subgenual cingulate.“ (Fox et al. Biol. Psychiatry 2012)
- “Individualized targeting becomes less important with larger stimulation field sizes.” (Fox et al. Neuroimage 2013)
Brainsway Deep TMS has been cleared by the FDA* for patients who tried any number of antidepressants with no improvement (in the current depressive episode). The FDA indication is based on a unique long-term 16-week double blind, placebo-controlled, multi-center study, which enrolled over 200 subjects, and reported a marked decline in HDRS-21 scores, as well as significant remission (32.6%) and response (38.4%) rates at the primary endpoint of the study after 4 weeks of acute treatment. In the study, Brainsway's treatment was proved to be safe, and the treatment was well tolerated by the majority of the study subjects.
Brainsway's TMS therapy is based on patents filed by the U.S. National Institutes of Health (NIH) and the company.
Brainsway Deep TMS is s short-term major depressive disorder treatment requiring only brief daily sessions of 20 minutes over 4-6 weeks. In each session, the patient is comfortably seated in a chair, and a cushioned helmet is gently placed over the head. The helmet generates brief magnetic fields, similar to those used in magnetic resonance imaging (MRI) systems. After each of Brainsway's TMS therapy sessions, patients can return home independently, and resume their daily routine.
The Brainsway Deep TMS System is indicated by the FDA for the treatment of depressive episodes in adult patients suffering from Major Depressive Disorder, who failed to achieve satisfactory improvement from previous anti-depressant medication treatment in the current episode. FDA 510(k) No. K122288